Publications by authors named "Pommeret F"
Article Synopsis
- Circulating proteomes can reveal the body's response to diseases like COVID-19 and treatments like tocilizumab, which is used to mitigate severe symptoms.
- In a study involving 28 hospitalized COVID-19 patients treated with tocilizumab, researchers collected serum samples to analyze changes in protein levels before and after treatment and assessed patient outcomes for 30 days.
- Findings indicated that specific proteins related to the complement system and Fc-epsilon receptor signaling could predict treatment success and mortality, where high complement activation linked to worse outcomes and certain signaling pathways showed lower mortality rates.
Background: To date, limited evidence exists on the impact of COVID-19 in patients with soft tissue sarcoma (STS), nor about the impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in this specific population.
Methods: We described COVID-19 morbidity and mortality among patients with STS across 'Omicron' (15 December 2021-31 January 2022), 'Pre-vaccination' (27 February 2020-30 November 2020), and 'Alpha-Delta' phase (01 December 2020-14 December 2021) using OnCovid registry participants (NCT04393974). Case fatality rate at 28 days (CFR) and COVID-19 severity were also described according to the SARS-CoV-2 vaccination status, while the impact of the receipt of cytotoxic chemotherapy within 4 weeks prior to COVID-19 on clinical outcomes was assessed with Inverse Probability of Treatment Weighting (IPTW) models adjusted for possible confounders.
Objectives: To date, studies have not provided definitive answers regarding whether previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with COVID-19.
Methods: The OnCovid registry (NCT04393974) was searched from February 27, 2020, to January 31, 2022, for patients who received systemic anti-cancer therapy in the 4 weeks before laboratory-confirmed COVID-19 diagnosis. Propensity-score matching using country, vaccination status, primary tumor type, sex, age, comorbidity burden, tumor stage, and remission status investigated differences in predefined clinical outcomes comparing those who had or had not received ICIs.
Article Synopsis
- The CORIPLASM trial aimed to assess whether covid-19 convalescent plasma is effective in treating hospitalized adults with moderate covid-19, including those with weakened immune systems.
- Conducted across 19 hospitals in France, the trial included 120 participants randomly assigned to receive either convalescent plasma or usual care between April 2020 and April 2021.
- Key outcomes measured included the proportion of patients experiencing worsening symptoms by day 4 and survival without needing assisted ventilation by day 14, while secondary outcomes assessed overall survival and recovery times.
Article Synopsis
- The study investigates whether prior exposure to immune checkpoint inhibitors (ICIs) impacts the severity of COVID-19 in cancer patients, analyzing data from two major registries.
- Out of 240 cancer patients diagnosed with COVID-19, it was found that vaccination significantly reduced the case fatality rate and related hospitalizations among those who had received ICIs.
- Additionally, patients who experienced immune-related adverse events (irAEs) prior to COVID-19 had a lower risk of death compared to those without irAEs, suggesting that these events may play a protective role.
Purpose: Patients enrolled in oncology phase 1 trials (ph1) usually have advanced heavily pre-treated cancers with few therapeutic options. Quality of life (QoL) is one of the key cancer-treatment outcome measures, especially in ph1, and sexuality is an important part of Qol but rarely explored. This prospective study aims to assess supportive care needs, QoL and sexuality in ph1.
View Article and Find Full Text PDFArticle Synopsis
- Older patients with ovarian cancer show a wide range of health statuses, prompting the creation of the geriatric vulnerability score (GVS) to predict treatment outcomes.
- The EWOC-1 study involved patients 70 and older with stage III or IV ovarian cancer, where those with a GVS of 3 or higher were treated with different chemotherapy regimens and evaluated for survival.
- Results indicated that higher GVS scores were linked to significantly poorer survival rates, establishing GVS as a critical tool for identifying vulnerable patients in oncological care.
Background: Anti-angiogenic rechallenge with bevacizumab plus chemotherapy is effective in recurrent ovarian cancer (rOC); however, data are limited on tyrosine kinase inhibitors after progression on maintenance bevacizumab.
Methods: In the randomized phase II TAPAZ trial, patients with rOC during the first year of bevacizumab maintenance therapy were assigned 2:1 to either weekly paclitaxel 65 mg/m plus pazopanib 600-800 mg daily or standard weekly paclitaxel 80 mg/m. The primary endpoint was 4-month progression-free survival (PFS) rate.
Background: Severe COVID-19 is associated with a high circulating level of calprotectin, the S100A8/S100A9 alarmin heterodimer. Baseline calprotectin amount measured in peripheral blood at diagnosis correlates with disease severity. The optimal use of this biomarker along COVID-19 course remains to be delineated.
View Article and Find Full Text PDFBackground: Fifteen percent of patients with cancer experience symptomatic sequelae, which impair post-COVID-19 outcomes. In this study, we investigated whether a proinflammatory status is associated with the development of COVID-19 sequelae.
Methods: OnCovid recruited 2795 consecutive patients who were diagnosed with Severe Acute Respiratory Syndrome Coronavirus 2 infection between February 27, 2020, and February 14, 2021.
Article Synopsis
- The study investigates how memory T cells respond to the SARS-CoV-2 virus and its variants, focusing on their link to protection against COVID-19 in healthy and cancer patients.
- Findings suggest that an imbalance in immune responses, particularly between type 1 and type 2 cytokines, increases vulnerability to the virus, especially in individuals with specific deficiencies in T helper 1 (Th1) cells.
- Current vaccines primarily trigger Th1 responses effectively against the original virus strain, highlighting the need for future vaccines to target T-cell responses against the receptor binding domain of new variants.
Article Synopsis
- The study aimed to determine if COVID-19 severity and death rates among patients with cancer improved over time during the pandemic.
- It utilized data from the OnCovid registry, which included nearly 2,800 patients with various types of cancer from 6 European countries, focusing on patient outcomes from February 2020 to February 2021.
- Results showed that the 14-day case-fatality rate significantly decreased over time, suggesting improved management and outcomes for cancer patients infected with COVID-19.
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry.
Ther Adv Med Oncol
November 2021
Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2 than other cancer patients.
Methods: We report a subanalysis of the OnCovid study providing more detailed information in the breast cancer population.
Article Synopsis
- The study investigates the impact of COVID-19 on cancer patients, focusing on the prevalence of long-term effects (sequelae) and their influence on patient survival.
- The research involved 2,634 eligible cancer patients who had confirmed SARS-CoV-2 infections and were assessed several months after recovery to analyze their health outcomes.
- Results showed 1,557 COVID-19 survivors underwent a formal reassessment about 22 months post-cancer diagnosis, revealing insights into the effects of COVID-19 on their treatment and survival.
Patients with cancer are at higher risk of severe coronavirus infectious disease 2019 (COVID-19), but the mechanisms underlying virus-host interactions during cancer therapies remain elusive. When comparing nasopharyngeal swabs from cancer and noncancer patients for RT-qPCR cycle thresholds measuring acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 1063 patients (58% with cancer), we found that malignant disease favors the magnitude and duration of viral RNA shedding concomitant with prolonged serum elevations of type 1 IFN that anticorrelated with anti-RBD IgG antibodies. Cancer patients with a prolonged SARS-CoV-2 RNA detection exhibited the typical immunopathology of severe COVID-19 at the early phase of infection including circulation of immature neutrophils, depletion of nonconventional monocytes, and a general lymphopenia that, however, was accompanied by a rise in plasmablasts, activated follicular T-helper cells, and non-naive Granzyme BFasL, EomesTCF-1, PD-1CD8 Tc1 cells.
View Article and Find Full Text PDFBackground: Despite high contagiousness and rapid spread, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to heterogeneous outcomes across affected nations. Within Europe (EU), the United Kingdom (UK) is the most severely affected country, with a death toll in excess of 100,000 as of January 2021. We aimed to compare the national impact of coronavirus disease 2019 (COVID-19) on the risk of death in UK patients with cancer versus those in continental EU.
View Article and Find Full Text PDFArticle Synopsis
- * Analysis found significant changes in 77 metabolites (like amino acids and sugars) in critical COVID-19 patients compared to those with mild symptoms.
- * Among moderately ill patients treated with tocilizumab, only 10 metabolites differed in those who improved versus those who worsened, with high levels of anthranilic acid linked to poor outcomes, suggesting potential therapeutic targets for treatment.
Objective: In young women, EOC is a rare disease with an uncertain genetic and biological substrate.
Methods: We report a long follow-up of EOC patients treated at Gustave Roussy between 1990 and 2009. We matched young patients aged ≤30 years to randomly selected older patients aged ≥40 years according to known prognostic factors (i.
Article Synopsis
- * Key factors affecting mortality included age over 70, smoking, metastatic disease, and a poor Eastern Cooperative Oncology Group score, with the latter being the strongest predictor.
- * Treatments like immunotherapy and targeted therapy did not worsen outcomes; however, biomarkers like C-reactive protein and D-dimer levels indicated increased risks, while COVID-19 management led to delays and changes in cancer treatments for many patients.
Article Synopsis
- Anti-CD20 monoclonal antibodies can lead to a lack of B-cells, making it hard for some patients to develop an antibody response to COVID-19.
- A study of 17 patients with low B-cell levels and ongoing COVID-19 symptoms showed significant improvement after receiving COVID-19 convalescent plasma, with most patients feeling better within 48 hours.
- The treatment was well-tolerated with no adverse effects, suggesting that convalescent plasma may be an effective option for those who struggle to produce antibodies against SARS-CoV-2.
Article Synopsis
- Blood myeloid cells show dysregulation in COVID-19, with changes in monocyte and neutrophil populations linked to disease severity.
- In severe cases, there's a notable decrease in non-classical CD14CD16 monocytes and an accumulation of HLA-DR classical monocytes, along with high levels of calprotectin.
- The findings suggest that measuring calprotectin levels and non-classical monocyte frequencies could help predict which COVID-19 patients are at higher risk for severe illness, indicating a need for further study.